輝瑞 PFE 深 滬
已收盤 02-06 16:00:00 美东时间
27.22
+0.730
+2.76%
華盛通- 最 高27.37
- 今 開26.67
- 成交量 5069.13万股
- 最 低 26.52
- 昨 收 26.49
- 總市值 1547.65亿
- 52周最高 27.37
- 市盈率 靜 20.01
- 換手率 0.89%
- 52周最低 19.195
- 委 比 4.66%
- 總股本 56.86亿
- 歷史最高 54.64
- 量 比 0.72
- 振 幅 3.21%
- 歷史最低 -3.0473
- 每 手 1
- 風險率 1.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多全球“药王”易主！医药巨头们的最新财报，透露了哪些“财富密码”？
（来源：ETF万亿指数） 最近美股财报季，同时A股、港股也部分医药公司也发了2025年全年业绩预告。 于是，整理了部分医药巨头的最新业绩情况，看看这些财报里面都...
今天 09:51
CVS pharmacies accepting TrumpRx discount cards
CVS Health (CVS) said that its network of around 9,000 pharmacies is accepting TrumpRx discount cards for prescription drugs. President Trump formally launched the TrumpRx program on Thursday evening....
02-07 05:45
AMZN’s free cash flow will go negative, GOOGL will not – analyst
Amazon’s (AMZN) free cash flow is likely to turn negative due to aggressive AI capital expenditures, while Google’s parent company (GOOGL), (GOOG) is expected to maintain positive cash flow despite si...
02-07 02:23
GoodRx becomes pricing source for Pfizer and other drugmakers on TrumpRx
GoodRx (GDRX) announced that it has become a major integration partner for Pfizer (PFE) and other pharmaceutical companies, which offer discounts on TrumpRx, a newly launched government website listin...
02-06 23:47
辉瑞抗感染创新药获批儿科适应证
2月6日，记者从辉瑞获悉，其抗感染领域创新药物硫酸艾沙康唑胶囊（商品名：康新博，规格：40mg）在国内获批，用于治疗体重≥16千克 （kg）的6岁至18岁以下儿...
02-06 22:17
Pfizer – Roivant tie-up generates positive mid-stage data for lead asset
Priovant Therapeutics, a company established in 2021 as part of a transaction between Pfizer (PFE) and Roivant Sciences (ROIV), announced positive mid-stage trial results for its lead asset, brepociti...
02-06 22:02
4 stocks to watch on Friday: PM, PFE, MSTR, HIMS
Stock index futures rose on Friday, a day after Wall Street’s sell-off, while investors digested Amazon’s earnings results. Here are the four stocks to watch on the day: Strategy (MSTR) shares jumped ...
02-06 21:56
Pfizer wins FDA priority review for Hympavzi label expansion
Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...
02-06 21:23
FDA prüft Zulassung von HYMPAVZI für Patienten mit Hämophilie und Inhibitoren
FDA prüft Zulassung von HYMPAVZI für Patienten mit Hämophilie und Inhibitoren Die US-amerikanische Zulassungsbehörde FDA hat die Priority Review für den ergänzenden Biologika-Zulassungsantrag (sBLA) von Pfizer Inc. für HYMPAVZI (marstacimab) angenommen. Der Antrag zielt auf die Erweiterung der Indik
02-06 19:45
FDA Grants Priority Review to Pfizer’s HYMPAVZI for Hemophilia Treatment
FDA Grants Priority Review to Pfizer’s HYMPAVZI for Hemophilia Treatment Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for its supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab). The application seeks to exp
02-06 19:45
公司簡介
公司名稱
|
辉瑞
|
行業分類
|
制药
|
業務描述
|
在辉瑞，我们致力于运用科学以及我们的全球资源来改善每个生命阶段的健康状况。在药品的探索、开发和生产过程中，我们多样化的全球保健产品包括生物药品、小分子药品和疫苗，以及许多世界驰名的健康药物。每天，世界各地的辉瑞员工致力于推进健康，以及能够应对我们这个时代最为棘手的疾病的预防和治疗方案。辉瑞还与世界各地的医疗卫生专业人士、政府和社区合作，支持世界各地的人们能够获得更为可靠和可承付的医疗卫生服务。这与辉瑞作为一家世界领先的生物制药公司的责任是一致的。160多年来，辉瑞一直努力为人们提供更好、更优质的服务。
2016年收入528亿美元，全球63个生产基地，业务遍布全球约175个国家和地区，有9种产品的销售额超过10亿美元，2016年新增140多个研发合作机构，全球96,500余名员工。
|
全球“药王”易主！医药巨头们的最新财报，透露了哪些“财富密码”？
（来源：ETF万亿指数） 最近美股财报季，同时A股、港股也部分医药公司也发了2025年全年业绩预告。 于是，整理了部分医药巨头的最新业绩情况，看看这些财报里面都...
今天 09:51
CVS pharmacies accepting TrumpRx discount cards
CVS Health (CVS) said that its network of around 9,000 pharmacies is accepting TrumpRx discount cards for prescription drugs. President Trump formally launched the TrumpRx program on Thursday evening....
02-07 05:45
AMZN’s free cash flow will go negative, GOOGL will not – analyst
Amazon’s (AMZN) free cash flow is likely to turn negative due to aggressive AI capital expenditures, while Google’s parent company (GOOGL), (GOOG) is expected to maintain positive cash flow despite si...
02-07 02:23
GoodRx becomes pricing source for Pfizer and other drugmakers on TrumpRx
GoodRx (GDRX) announced that it has become a major integration partner for Pfizer (PFE) and other pharmaceutical companies, which offer discounts on TrumpRx, a newly launched government website listin...
02-06 23:47
辉瑞抗感染创新药获批儿科适应证
2月6日，记者从辉瑞获悉，其抗感染领域创新药物硫酸艾沙康唑胶囊（商品名：康新博，规格：40mg）在国内获批，用于治疗体重≥16千克 （kg）的6岁至18岁以下儿...
02-06 22:17
Pfizer – Roivant tie-up generates positive mid-stage data for lead asset
Priovant Therapeutics, a company established in 2021 as part of a transaction between Pfizer (PFE) and Roivant Sciences (ROIV), announced positive mid-stage trial results for its lead asset, brepociti...
02-06 22:02
4 stocks to watch on Friday: PM, PFE, MSTR, HIMS
Stock index futures rose on Friday, a day after Wall Street’s sell-off, while investors digested Amazon’s earnings results. Here are the four stocks to watch on the day: Strategy (MSTR) shares jumped ...
02-06 21:56
Pfizer wins FDA priority review for Hympavzi label expansion
Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...
02-06 21:23
FDA prüft Zulassung von HYMPAVZI für Patienten mit Hämophilie und Inhibitoren
FDA prüft Zulassung von HYMPAVZI für Patienten mit Hämophilie und Inhibitoren Die US-amerikanische Zulassungsbehörde FDA hat die Priority Review für den ergänzenden Biologika-Zulassungsantrag (sBLA) von Pfizer Inc. für HYMPAVZI (marstacimab) angenommen. Der Antrag zielt auf die Erweiterung der Indik
02-06 19:45
FDA Grants Priority Review to Pfizer’s HYMPAVZI for Hemophilia Treatment
FDA Grants Priority Review to Pfizer’s HYMPAVZI for Hemophilia Treatment Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for its supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab). The application seeks to exp
02-06 19:45
派息除權日
|
每股總股息
| 派息日期 |
2026-01-23
|
0.43
|
2026-03-06
|
2025-11-07
|
0.43
|
2025-12-01
|
2025-07-25
|
0.43
|
2025-09-02
|
2025-05-09
|
0.43
|
2025-06-13
|
2025-01-24
|
0.43
|
2025-03-07
|
2024-11-08
|
0.42
|
2024-12-02
|
2024-07-26
|
0.42
|
2024-09-03
|
2024-05-09
|
0.42
|
2024-06-14
|
2024-01-25
|
0.42
|
2024-03-01
|
2023-11-09
|
0.41
|
2023-12-04
|
2023-07-27
|
0.41
|
2023-09-05
|
2023-05-11
|
0.41
|
2023-06-09
|
2023-01-26
|
0.41
|
2023-03-03
|
2022-11-03
|
0.40
|
2022-12-05
|
2022-07-28
|
0.40
|
2022-09-06
|
2022-05-12
|
0.40
|
2022-06-10
|
2022-01-27
|
0.40
|
2022-03-04
|
2021-11-04
|
0.39
|
2021-12-06
|
2021-07-29
|
0.39
|
2021-09-07
|
2021-05-06
|
0.39
|
2021-06-04
|
2021-01-28
|
0.39
|
2021-03-05
|
2020-11-05
|
0.38
|
2020-12-01
|
2020-07-30
|
0.38
|
2020-09-01
|
2020-05-07
|
0.38
|
2020-06-05
|
2020-01-30
|
0.38
|
2020-03-06
|
2019-11-07
|
0.36
|
2019-12-02
|
2019-08-01
|
0.36
|
2019-09-03
|
2019-05-09
|
0.36
|
2019-06-07
|
2019-01-31
|
0.36
|
2019-03-01
|
2018-11-08
|
0.34
|
2018-12-03
|
2018-08-02
|
0.34
|
2018-09-04
|
2018-05-10
|
0.34
|
2018-06-01
|
2018-02-01
|
0.34
|
2018-03-01
|
2017-11-09
|
0.32
|
2017-12-01
|
2017-08-02
|
0.32
|
2017-09-01
|
2017-05-10
|
0.32
|
2017-06-01
|
2017-02-01
|
0.32
|
2017-03-01
|
2016-11-08
|
0.30
|
2016-12-01
|
2016-08-03
|
0.30
|
2016-09-01
|
2016-05-11
|
0.30
|
2016-06-01
|
2016-02-03
|
0.30
|
2016-03-02
|
2015-11-04
|
0.28
|
2015-12-01
|
2015-08-05
|
0.28
|
2015-09-02
|
2015-05-06
|
0.28
|
2015-06-02
|
2015-02-04
|
0.28
|
2015-03-03
|
2014-11-05
|
0.26
|
2014-12-02
|
2014-07-30
|
0.26
|
2014-09-03
|
2014-05-07
|
0.26
|
2014-06-03
|
2014-02-05
|
0.26
|
2014-03-04
|
2013-11-06
|
0.24
|
2013-12-03
|
2013-07-31
|
0.24
|
2013-09-04
|
2013-05-08
|
0.24
|
2013-06-04
|
2013-01-30
|
0.24
|
2013-03-05
|
2012-11-07
|
0.22
|
2012-12-04
|
2012-08-01
|
0.22
|
2012-09-05
|
2012-05-09
|
0.22
|
2012-06-05
|
2012-02-01
|
0.22
|
2012-03-06
|
2011-11-08
|
0.20
|
2011-12-06
|
2011-08-03
|
0.20
|
2011-09-06
|
2011-05-11
|
0.20
|
2011-06-07
|
2011-02-02
|
0.20
|
2011-03-01
|
2010-11-04
|
0.18
|
2010-12-01
|
2010-08-04
|
0.18
|
2010-09-01
|
2010-05-05
|
0.18
|
2010-06-01
|
2010-02-03
|
0.18
|
2010-03-02
|
2009-11-04
|
0.16
|
2009-12-01
|
2009-08-05
|
0.16
|
2009-09-02
|
2009-05-06
|
0.16
|
2009-06-02
|
2009-02-04
|
0.32
|
2009-03-03
|
2008-11-05
|
0.32
|
2008-12-02
|
2008-08-06
|
0.32
|
2008-09-03
|
2008-05-07
|
0.32
|
2008-06-03
|
2008-02-06
|
0.32
|
2008-03-04
|
2007-11-07
|
0.29
|
2007-12-04
|
2007-08-08
|
0.29
|
2007-09-05
|
2007-05-09
|
0.29
|
2007-06-05
|
2007-02-07
|
0.29
|
2007-03-06
|
2006-11-08
|
0.24
|
2006-12-05
|
2006-08-09
|
0.24
|
2006-09-05
|
2006-05-10
|
0.24
|
2006-06-06
|
2006-02-08
|
0.24
|
2006-03-07
|
2005-11-08
|
0.19
|
2005-12-06
|
2005-08-10
|
0.19
|
2005-09-06
|
2005-05-11
|
0.19
|
2005-06-07
|
2005-02-09
|
0.19
|
2005-03-08
|
2004-11-09
|
0.17
|
2004-12-03
|
2004-08-11
|
0.17
|
2004-09-03
|
2004-05-12
|
0.17
|
2004-06-04
|
2004-02-11
|
0.17
|
2004-03-05
|
2003-11-12
|
0.15
|
2003-12-04
|
2003-08-13
|
0.15
|
2003-09-04
|
2003-05-14
|
0.15
|
2003-06-05
|
2003-01-15
|
0.15
|
2003-02-14
|
2002-11-13
|
0.13
|
2002-12-05
|
2002-08-14
|
0.13
|
2002-09-05
|
2002-05-15
|
0.13
|
2002-06-06
|
2002-02-13
|
0.13
|
2002-03-07
|
2001-11-14
|
0.11
|
2001-12-06
|
2001-08-15
|
0.11
|
2001-09-06
|
2001-05-16
|
0.11
|
2001-06-07
|
2001-02-14
|
0.11
|
2001-03-08
|
2000-11-15
|
0.09
|
2000-12-07
|
2000-08-16
|
0.09
|
2000-09-07
|
2000-05-09
|
0.09
|
2000-06-08
|
2000-02-16
|
0.09
|
2000-03-09
|
1999-11-09
|
0.08
|
1999-12-09
|
1999-08-04
|
0.08
|
1999-09-09
|
1999-05-05
|
0.22
|
1999-06-10
|
1999-02-10
|
0.22
|
1999-03-11
|
1998-11-04
|
0.19
|
1998-12-10
|
1998-08-05
|
0.19
|
1998-09-10
|
1998-05-06
|
0.19
|
1998-06-11
|
1998-02-04
|
0.19
|
1998-03-12
|
1997-11-05
|
0.17
|
1997-12-11
|
1997-07-30
|
0.17
|
1997-09-11
|
1997-05-07
|
0.34
|
1997-06-12
|
1997-02-05
|
0.34
|
1997-03-13
|
1996-11-06
|
0.30
|
1996-12-12
|
1996-07-31
|
0.30
|
1996-09-12
|
1996-05-08
|
0.30
|
1996-06-13
|
1996-02-07
|
0.30
|
1996-03-14
|
1995-11-08
|
0.26
|
1995-12-21
|
1995-08-02
|
0.26
|
1995-09-21
|
1995-05-08
|
0.52
|
1995-06-15
|
1995-02-06
|
0.52
|
1995-03-16
|
1994-11-04
|
0.47
|
1994-12-15
|
1994-08-01
|
0.47
|
1994-09-15
|
1994-05-09
|
0.47
|
1994-06-16
|
1994-02-07
|
0.47
|
1994-03-17
|
1993-11-05
|
0.42
|
1993-12-16
|
1993-08-02
|
0.42
|
1993-09-16
|
1993-05-10
|
0.42
|
1993-06-17
|
1993-02-08
|
0.42
|
1993-03-18
|
1992-11-16
|
0.37
|
1992-12-17
|
1992-08-03
|
0.37
|
1992-09-17
|
1992-05-11
|
0.37
|
1992-06-18
|
1992-02-03
|
0.37
|
1992-03-19
|
1991-11-08
|
0.33
|
1991-12-19
|
1991-08-01
|
0.33
|
1991-09-19
|
1991-05-13
|
0.33
|
1991-06-20
|
1991-02-22
|
0.66
|
1991-03-21
|
1990-11-09
|
0.60
|
1990-12-20
|
1990-08-06
|
0.60
|
1990-09-20
|
1990-05-14
|
0.60
|
1990-06-21
|
1990-02-05
|
0.60
|
1990-03-22
|
1989-11-13
|
0.55
|
1989-12-21
|
1989-07-24
|
0.55
|
1989-09-21
|
1989-05-15
|
0.55
|
1989-06-21
|
1989-01-23
|
0.55
|
1989-03-22
|
1988-11-15
|
0.50
|
1988-12-20
|
1988-07-25
|
0.50
|
1988-09-20
|
1988-05-16
|
0.50
|
1988-06-20
|
1988-02-12
|
0.50
|
1988-03-21
|
1987-11-16
|
0.45
|
1987-12-21
|
1987-07-27
|
0.45
|
1987-09-21
|
1987-05-14
|
0.45
|
1987-06-19
|
1987-01-26
|
0.45
|
1987-03-20
|
1986-11-17
|
0.41
|
1986-12-19
|
1986-07-28
|
0.41
|
1986-09-19
|
1986-05-14
|
0.41
|
1986-06-20
|
1986-01-27
|
0.41
|
1986-03-21
|
1985-11-15
|
0.37
|
1985-12-20
|
1985-07-26
|
0.37
|
1985-09-20
|
1985-05-20
|
0.37
|
1985-06-21
|
1985-01-28
|
0.37
|
1985-03-21
|
1984-11-13
|
0.33
|
1984-12-20
|
1984-07-26
|
0.33
|
1984-09-20
|
1984-05-14
|
0.33
|
1984-06-21
|
1984-01-26
|
0.33
|
1984-03-21
|
1983-11-14
|
0.29
|
1983-12-21
|
1983-07-26
|
0.29
|
1983-09-21
|
1983-05-13
|
0.58
|
1983-06-21
|
1983-01-26
|
0.58
|
1983-03-21
|
1982-11-15
|
0.46
|
1982-12-21
|
1982-07-27
|
0.46
|
1982-09-21
|
1982-05-13
|
0.46
|
1982-06-21
|
1982-01-26
|
0.46
|
1982-03-19
|
1981-11-13
|
0.40
|
1981-12-21
|
1981-08-13
|
0.40
|
1981-09-21
|
1981-05-13
|
0.40
|
1981-06-19
|
1981-02-11
|
0.40
|
1981-03-20
|
1980-11-28
|
0.36
|
1980-12-22
|
1980-09-02
|
0.36
|
1980-09-29
|
1980-05-29
|
0.36
|
1980-06-27
|
1980-03-03
|
0.36
|
1980-03-30
|
1979-11-22
|
0.33
|
1979-12-18
|
1979-08-27
|
0.33
|
1979-09-20
|
1979-05-23
|
0.33
|
1979-06-21
|
1979-03-05
|
0.33
|
1979-03-29
|
1978-11-21
|
0.30
|
1978-12-17
|
1978-08-28
|
0.30
|
1978-09-21
|
1978-05-25
|
0.30
|
1978-06-22
|
1978-02-27
|
0.27
|
1978-03-23
|
1977-11-24
|
0.27
|
1977-12-18
|
1977-09-01
|
0.24
|
1977-09-22
|
1977-05-30
|
0.24
|
1977-06-23
|
1977-02-28
|
0.24
|
1977-03-24
|
